Investigational drugs for the treatment of spinal cord injury: Review of preclinical studies and evaluation of clinical trials from Phase i to II

Expert Opinion on Investigational Drugs

Volumn 24, Issue 5, 2015, Pages 645-658

  Nagoshi, Narihito ^a,b   Fehlings, Michael G ^a,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Basic fibroblast growth factor; Clinical trials in Phase II; Magnesium; Minocycline; Rho protein antagonist; Riluzole; Spinal cord injury

Indexed keywords

MACROGOL; MAGNESIUM CHLORIDE; MINOCYCLINE; PROTEIN INHIBITOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RHO FACTOR; RHO KINASE; RHO PROTEIN ANTAGONIST; RILUZOLE; UNCLASSIFIED DRUG; NEW DRUG;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; ANIMAL; DRUG DESIGN; DRUG SCREENING; OUTCOME ASSESSMENT; SPINAL CORD INJURIES;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SPINAL CORD INJURIES;

EID: 84927618396     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1009629     Document Type: Review

References (101)

1. Furlan JC, Sakakibara BM, Miller WC, et al. Global incidence and prevalence of traumatic spinal cord injury. Can J Neurol Sci 2013;40:456-64
2. Spinal cord injury facts and figures at a glance. J Spinal Cord Med 2013;36:170-1
3. Noonan VK, Fingas M, Farry A, et al. Incidence and prevalence of spinal cord injury in Canada: a national perspective. Neuroepidemiology 2012;38:219-26
4. Fehlings MG, Vaccaro A, Wilson JR, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS One 2012;7:e32037
5. Wilson JR, Singh A, Craven C, et al. Early versus late surgery for traumatic spinal cord injury: the results of a prospective Canadian cohort study. Spinal Cord 2012;50:840-3
6. Labruyere R, Agarwala A, Curt A. Rehabilitation in spine and spinal cord trauma. Spine 2010;35:S259-62
7. Hurlbert RJ. Methylprednisolone for the treatment of acute spinal cord injury: point. Neurosurgery 2014;61(Suppl 1):32-5
8. Fehlings MG, Wilson JR, Cho N. Methylprednisolone for the treatment of acute spinal cord injury: counterpoint. Neurosurgery 2014;61(Suppl 1):36-42
9. Kwon BK, Okon E, Hillyer J, et al. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 2011;28:1545-88
10. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, et al. A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma 2011;28:1611-82
11. Schwartz G, Fehlings MG. Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res 2002;137:177-90
12. Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol 2004;3:744-51
13. Harrop JS, Hashimoto R, Norvell D, et al. Evaluation of clinical experience using cell-based therapies in patients with spinal cord injury: a systematic review. J Neurosurg Spine 2012;17:230-46
14. Wilson JR, Forgione N, Fehlings MG. Emerging therapies for acute traumatic spinal cord injury. CMAJ 2013;185:485-92
15. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26
16. Schanne FA, Kane AB, Young EE, et al. Calcium dependence of toxic cell death: a final common pathway. Science 1979;206:700-2
17. Park E, Velumian AA, Fehlings MG. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma 2004;21:754-74
18. Schnell L, Fearn S, Schwab ME, et al. Cytokine-induced acute inflammation in the brain and spinal cord. J Neuropathol Exp Neurol 1999;58:245-54
19. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000;403:434-9
20. Domeniconi M, Cao Z, Spencer T, et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 2002;35:283-90
21. Wang KC, Koprivica V, Kim JA, et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002;417:941-4
22. Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001;409:341-6
23. Forgione N, Fehlings MG. Rho-ROCK inhibition in the treatment of spinal cord injury. World Neurosurg 2014;82(3-4):e535-9
24. Morgenstern DA, Asher RA, Fawcett JW. Chondroitin sulphate proteoglycans in the CNS injury response. Prog Brain Res 2002;137:313-32
25. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004;5:146-56
26. Dergham P, Ellezam B, Essagian C, et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002;22:6570-7
27. Lord-Fontaine S, Yang F, Diep Q, et al. Local inhibition of Rho signaling by cellpermeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J Neurotrauma 2008;25:1309-22
28. Freund P, Wannier T, Schmidlin E, et al. Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 2007;502:644-59
29. Bradbury EJ, Moon LD, Popat RJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002;416:636-40
30. Fehlings MG, Wilson JR, Frankowski RF, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. J Neurosurg Spine 2012;17:151-6
31. Agrawal SK, Fehlings MG. Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+, Na(+)-K(+)- ATPase, the Na(+)-H+ exchanger, and the Na(+)-Ca2+ exchanger. J Neurosci 1996;16:545-52
32. Stys PK, Waxman SG, Ransom BR. Na (+)-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter. Ann Neurol 1991;30:375-80
33. Haigney MC, Lakatta EG, Stern MD, et al. Sodium channel blockade reduces hypoxic sodium loading and sodiumdependent calcium loading. Circulation 1994;90:391-9
34. Haigney MC, Miyata H, Lakatta EG, et al. Dependence of hypoxic cellular calcium loading on Na(+)-Ca2+ exchange. Circ Res 1992;71:547-57
35. Li S, Mealing GA, Morley P, et al. Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+- dependent glutamate transport. J Neurosci 1999;19:RC16
36. Kobrine AI, Evans DE, LeGrys DC, et al. Effect of intravenous lidocaine on experimental spinal cord injury. J Neurosurg 1984;60:595-601
37. Teng YD, Wrathall JR. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J Neurosci 1997;17:4359-66
38. Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002;249:609-15
39. Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001;94:245-56
40. Wu Y, Satkunendrarajah K, Teng Y, et al. Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J Neurotrauma 2013;30:441-52
41. Kwon BK, Stammers AM, Belanger LM, et al. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 2010;27:669-82
42. Wu Y, Satkunendrarajah K, Fehlings MG. Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia. Neuroscience 2014;265:302-12
43. Grossman RG, Fehlings MG, Frankowski RF, et al. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma 2014;31:239-55
44. Grossman RG, Toups EG, Frankowski RF, et al. North American Clinical Trials Network for the Treatment of Spinal Cord Injury: goals and progress. J Neurosurg Spine 2012;17:6-10
45. Stirling DP, Koochesfahani KM, Steeves JD, et al. Minocycline as a neuroprotective agent. Neuroscientist 2005;11:308-22
46. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769-74
47. Cho DC, Cheong JH, Yang MS, et al. The effect of minocycline on motor neuron recovery and neuropathic pain in a rat model of spinal cord injury. J Korean Neurosurg Soc 2011;49:83-91
48. Festoff BW, Ameenuddin S, Arnold PM, et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006;97:1314-26
49. Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003;20:1017-27
50. Sonmez E, Kabatas S, Ozen O, et al. Minocycline treatment inhibits lipid peroxidation, preserves spinal cord ultrastructure, and improves functional outcome after traumatic spinal cord injury in the rat. Spine 2013;38:1253-9
51. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-90
52. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 2004;101:3071-6
53. Wells JE, Hurlbert RJ, Fehlings MG, et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126:1628-37
54. Yune TY, Lee JY, Jung GY, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 2007;27:7751-61
55. Lee JH, Tigchelaar S, Liu J, et al. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury. Exp Neurol 2010;225:219-30
56. Pinzon A, Marcillo A, Quintana A, et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res 2008;1243:146-51
57. Saganova K, Orendacova J, Cizkova D, et al. Limited minocycline neuroprotection after ballooncompression spinal cord injury in the rat. Neurosci Lett 2008;433:246-9
58. Gomes-Leal W. Microglial physiopathology: how to explain the dual role of microglia after acute neural disorders? Brain Behav 2012;2:345-56
59. Casha S, Zygun D, McGowan MD, et al. Results of a phase II placebocontrolled randomized trial of minocycline in acute spinal cord injury. Brain 2012;135:1224-36
60. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-98
61. Raad M, El Tal T, Gul R, et al. Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis 2012;33:3659-68
62. Monnier PP, Sierra A, Schwab JM, et al. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol Cell Neurosci 2003;22:319-30
63. Dillon ST, Feig LA. Purification and assay of recombinant C3 transferase. Methods Enzymol 1995;256:174-84
64. Lehmann M, Fournier A, Selles-Navarro I, et al. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci 1999;19:7537-47
65. Dubreuil CI, Winton MJ, McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 2003;162:233-43
66. Watzlawick R, Sena ES, Dirnagl U, et al. Effect and reporting bias of RhoA/ ROCK-blockade intervention on locomotor recovery after spinal cord injury: a systematic review and meta-analysis. JAMA Neurol 2014;71:91-9
67. Fehlings MG, Theodore N, Harrop J, et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 2011;28:787-96
68. Guest JD, Hesse D, Schnell L, et al. Influence of IN-1 antibody and acidic FGF-fibrin glue on the response of injured corticospinal tract axons to human Schwann cell grafts. J Neurosci Res 1997;50:888-905
69. McKerracher L, Anderson KD. Analysis of recruitment and outcomes in the phase I/IIa Cethrin clinical trial for acute spinal cord injury. J Neurotrauma 2013;30:1795-804
70. Faden AI, Demediuk P, Panter SS, et al. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798-800
71. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001;2:241-71
72. Kwon BK, Sekhon LH, Fehlings MG. Emerging repair, regeneration, and translational research advances for spinal cord injury. Spine 2010;35:S263-70
73. Kaptanoglu E, Beskonakli E, Okutan O, et al. Effect of magnesium sulphate in experimental spinal cord injury: evaluation with ultrastructural findings and early clinical results. J Clin Neurosci 2003;10:329-34
74. Kaptanoglu E, Beskonakli E, Solaroglu I, et al. Magnesium sulfate treatment in experimental spinal cord injury: emphasis on vascular changes and early clinical results. Neurosurg Rev 2003;26:283-7
75. Suzer T, Coskun E, Islekel H, et al. Neuroprotective effect of magnesium on lipid peroxidation and axonal function after experimental spinal cord injury. Spinal Cord 1999;37:480-4
76. Kwon BK, Roy J, Lee JH, et al. Magnesium chloride in a polyethylene glycol formulation as a neuroprotective therapy for acute spinal cord injury: preclinical refinement and optimization. J Neurotrauma 2009;26:1379-93
77. Teng YD, Mocchetti I, Taveira-DaSilva AM, et al. Basic fibroblast growth factor increases longterm survival of spinal motor neurons and improves respiratory function after experimental spinal cord injury. J Neurosci 1999;19:7037-47
78. Teng YD, Mocchetti I, Wrathall JR. Basic and acidic fibroblast growth factors protect spinal motor neurones in vivo after experimental spinal cord injury. Eur J Neurosci 1998;10:798-802
79. Zhang HY, Wang ZG, Wu FZ, et al. Regulation of autophagy and ubiquitinated protein accumulation by bFGF promotes functional recovery and neural protection in a rat model of spinal cord injury. Mol Neurobiol 2013;48:452-64
80. Zhang HY, Zhang X, Wang ZG, et al. Exogenous basic fibroblast growth factor inhibits ER stress-induced apoptosis and improves recovery from spinal cord injury. CNS Neurosci Ther 2013;19:20-9
81. Bregman BS, Kunkel-Bagden E, Schnell L, et al. Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 1995;378:498-501
82. Caroni P, Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron 1988;1:85-96
83. Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 2006;12:790-2
84. GrandPre T, Nakamura F, Vartanian T, et al. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000;403:439-44
85. Hug A, Weidner N. From bench to beside to cure spinal cord injury: lost in translation? Int Rev Neurobiol 2012;106:173-96
86. Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004;1:80-100
87. Hurlbert RJ, Hadley MN, Walters BC, et al. Pharmacological therapy for acute spinal cord injury. Neurosurgery 2013;72(Suppl 2):93-105
88. Hawryluk GW, Rowland J, Kwon BK, et al. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 2008;25:E14
89. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995;12:1-21
90. Kwon BK, Okon EB, Tsai E, et al. A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury. J Neurotrauma 2011;28:1525-43
91. Adams M, Cavanagh JF. International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP): another step forward for spinal cord injury research. Spinal Cord 2004;42:273-80
92. Steeves JD, Lammertse D, Curt A, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007;45:206-21
93. Fujiyoshi K, Yamada M, Nakamura M, et al. In vivo tracing of neural tracts in the intact and injured spinal cord of marmosets by diffusion tensor tractography. J Neurosci 2007;27:11991-8
94. Konomi T, Fujiyoshi K, Hikishima K, et al. Conditions for quantitative evaluation of injured spinal cord by in vivo diffusion tensor imaging and tractography: preclinical longitudinal study in common marmosets. Neuroimage 2012;63:1841-53
95. Freund P, Weiskopf N, Ashburner J, et al. MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study. Lancet Neurol 2013;12:873-81
96. Cadotte DW, Bosma R, Mikulis D, et al. Plasticity of the injured human spinal cord: insights revealed by spinal cord functional MRI. PLoS One 2012;7:e45560
97. Cohen-Adad J, El Mendili MM, Lehericy S, et al. Demyelination and degeneration in the injured human spinal cord detected with diffusion and magnetization transfer MRI. Neuroimage 2011;55:1024-33
98. Yokobori S, Zhang Z, Moghieb A, et al. Acute Diagnostic Biomarkers for Spinal Cord Injury: Review of the Literature and Preliminary Research Report. World Neurosurg 2013. [Epub ahead of print]
99. Hayakawa K, Okazaki R, Ishii K, et al. Phosphorylated neurofilament subunit NF-H as a biomarker for evaluating the severity of spinal cord injury patients, a pilot study. Spinal Cord 2012;50:493-6
100. Kuhle J, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print]
101. Pouw MH, Kwon BK, Verbeek MM, et al. Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. Spinal Cord 2014;52:428-33